<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908126</url>
  </required_header>
  <id_info>
    <org_study_id>OXB-002</org_study_id>
    <nct_id>NCT02908126</nct_id>
  </id_info>
  <brief_title>Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility</brief_title>
  <official_title>Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oxytone Bioscience BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxytone Bioscience BV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I open-label, parallel-group clinical study in healthy term pregnant females
      undergoing a caesarean section. Two administrations of oxytocin will be tested, after which
      uterine contractility will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine contractility: area under the curve (AUC)</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Post Partum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin intravenous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of intravenous (IV) oxytocin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of oxytocin tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin drug</description>
    <arm_group_label>Oxytocin intravenous</arm_group_label>
    <arm_group_label>Oxytocin tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, term pregnant female with a gestational age of 37-42 weeks (singleton)

          -  Undergoing a planned primary and uncomplicated caesarean section (CS) for their first
             born under regional anaesthesia

          -  Aged between 18 and 40 years (both inclusive)

          -  Ability to communicate well with the Investigator and to comply with the requirements
             of the entire study

          -  Willing to give informed consent in writing.

        Exclusion Criteria:

          -  Being obese with BMI â‰¥35 before pregnancy

          -  History of, or existing thromboembolic, cardiovascular or cerebrovascular disorder

          -  History of cervical cancer

          -  History of severe infection of the uterus

          -  Previous surgery of the cervix or uterus or any other (previous) condition that could
             interfere with the measurement of uterine contractility

          -  Any clinically significant abnormality following review of medical history, laboratory
             result and physical examination at screening as judged by the Investigator

          -  Conditions or disorders that might affect the absorption, distribution, metabolism or
             excretion of any of the study medication

          -  Contraindications for oxytocin use

          -  Hypersensitivity to the active substances or to any of the excipients of the
             investigational product (test product or comparator drug)

          -  Present use or use within 30 days before the start of the study medication of one or
             more of the following medications: antihypertensive drugs, anti-coagulant therapy,
             medication that could affect myometrial contractility, sex steroids, prostaglandins
             and its analogues, inhalation anaesthetics, vasoconstrictors/sympathomimetics and
             caudal anaesthetics, vasopressin-like drugs

          -  Administration of any other investigational drug within 3 months before first dosing

          -  Tobacco use (smoking or snuffing), currently or within the last 6 months before
             screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska Institute, Danderyd hospital,Dept of Obstetrics and Gynecology</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Kopp-Kallner, MD</last_name>
      <phone>+46 8-12357022</phone>
      <email>mailto:Helena.Kopp-kallner@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

